

Breast Cancer Research International Symposium *in Honour of Dr. Charles Theillet*

Monday 12th December, 2022 – IRCM

- 11: 00 **Introduction (Dr. Charles Theillet, Dr. Claude Sardet, Pr. Philippe Jeanteur, representatives of the IRCM and SIRIC direction, Inserm, University of Montpellier, ICM)**
- 11h30 **Pr. Mohamed Bentires-Alj**
Professor of Experimental Surgical Oncology, University of Basel
Head of the Tumor Heterogeneity, Metastasis and Resistance Team at the Department of Biomedicine, University Hospital in Basel, Switzerland
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
- 12h10 **Pr. Carlos Caldas (by Visio)**
Professor of Cancer Medicine, University of Cambridge
Director of the Cambridge Breast Cancer Research Unit, Cancer Research UK Cambridge Institute, Cambridge, UK.
Breast cancer stratification and therapy response prediction in 2022
- 12h50 **Lunch**
- 14h00 **Dr. Christophe Ginestier**
DR Inserm, Head of the Inserm Team "Epithelial Stem Cells and Cancer"
Marseille Cancer Research Center, INSERM, CNRS, University of Marseille, Paoli Calmette Institute, Marseille, France
Uprooting breast tumors heterogeneity
- 14h40 **Pr. Gergely Szakacs**
Head of Team "Chemical Safety and Cancer Prevention », Center for Cancer Research, Medical University of Vienna, Austria
Targeting Drug-tolerant Persisters: a paradigm shift to conquer therapy resistant triple negative breast cancer (TNBC).
- 15h20 **Coffee break**
- 15h30 **Pr. William Jacot**
PU-PH Medical Oncology department of Montpellier Cancer Institute (ICM Unicancer)
Montpellier University Medical Faculty, IRCM Inserm U1194, France
HER2 in breast cancer: from oncogenic driver to Trojan horse
- 16h10 **Dr. Daniel Birnbaum**
DR Emeritus Inserm
Marseille Cancer Research Center, INSERM, CNRS, University of Marseille, Paoli Calmette Institute, Marseille, France
Breast Cancer Research, good old' days
- 17h00 **Dr. Charles Theillet et al. - Conclusion**